Click for best price
Targeted Drug VEGF Inhibitors for NSCLC Market Size, Share 2024
| Market size in 2024 |
US$ 2.89 billion
|
Forecast Market size by 2030 |
US$ 4.56 billion
|
| Growth Rate |
CAGR of 7.9% |
Number of Pages |
122 Pages |
The global Targeted Drug VEGF Inhibitors for NSCLC market size was valued at US$ 2.89 billion in 2024 and is projected to reach US$ 4.56 billion by 2030, at a CAGR of 7.9% during the forecast period 2024-2030.
United States Targeted Drug VEGF Inhibitors for NSCLC market size was valued at US$ 941 million in 2024 and is projected to reach US$ 1.43 billion by 2030, at a CAGR of 7.2% during the forecast period 2024-2030.
Drugs targeting the VEGF pathway to inhibit angiogenesis in non-small cell lung cancer.
Growth driven by established efficacy in combination with chemotherapy. Increasing use in maintenance therapy settings. Development of new formulations and delivery methods for improved patient outcomes.
Report Overview
This report provides a deep insight into the global Targeted Drug VEGF Inhibitors for NSCLC market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Targeted Drug VEGF Inhibitors for NSCLC Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Targeted Drug VEGF Inhibitors for NSCLC market in any manner.
Global Targeted Drug VEGF Inhibitors for NSCLC Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Roche
- Pfizer
- Allergan
- Amgen
- Biocon
- Reliance Lifesciences
- Beaconpharma
- Celgene Corporation
- Fujifilm Kyowa Kirin Biologics
- Hetero Drugs
Market Segmentation (by Type)
Market Segmentation (by Application)
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Targeted Drug VEGF Inhibitors for NSCLC Market
- Overview of the regional outlook of the Targeted Drug VEGF Inhibitors for NSCLC Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
| Report Attributes |
Report Details |
| Report Title |
Global Targeted Drug VEGF Inhibitors for NSCLC Market Research Report 2024(Status and Outlook) |
| Market size in 2024 |
US$ 2.89 billion
|
| Forecast Market size by 2030 |
US$ 4.56 billion
|
| Growth Rate |
CAGR of 7.9% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
122 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Targeted Drug VEGF Inhibitors for NSCLC
1.2 Key Market Segments
1.2.1 Targeted Drug VEGF Inhibitors for NSCLC Segment by Type
1.2.2 Targeted Drug VEGF Inhibitors for NSCLC Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Targeted Drug VEGF Inhibitors for NSCLC Market Overview
2.1 Global Market Overview
2.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Targeted Drug VEGF Inhibitors for NSCLC Market Competitive Landscape
3.1 Global Targeted Drug VEGF Inhibitors for NSCLC Sales by Manufacturers (2019-2024)
3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Manufacturers (2019-2024)
3.3 Targeted Drug VEGF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Targeted Drug VEGF Inhibitors for NSCLC Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Targeted Drug VEGF Inhibitors for NSCLC Sales Sites, Area Served, Product Type
3.6 Targeted Drug VEGF Inhibitors for NSCLC Market Competitive Situation and Trends
3.6.1 Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Rate
3.6.2 Global 5 and 10 Largest Targeted Drug VEGF Inhibitors for NSCLC Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Targeted Drug VEGF Inhibitors for NSCLC Industry Chain Analysis
4.1 Targeted Drug VEGF Inhibitors for NSCLC Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Targeted Drug VEGF Inhibitors for NSCLC Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Targeted Drug VEGF Inhibitors for NSCLC Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Type (2019-2024)
6.3 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2019-2024)
6.4 Global Targeted Drug VEGF Inhibitors for NSCLC Price by Type (2019-2024)
7 Targeted Drug VEGF Inhibitors for NSCLC Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Sales by Application (2019-2024)
7.3 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (M USD) by Application (2019-2024)
7.4 Global Targeted Drug VEGF Inhibitors for NSCLC Sales Growth Rate by Application (2019-2024)
8 Targeted Drug VEGF Inhibitors for NSCLC Market Segmentation by Region
8.1 Global Targeted Drug VEGF Inhibitors for NSCLC Sales by Region
8.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Sales by Region
8.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Region
8.2 North America
8.2.1 North America Targeted Drug VEGF Inhibitors for NSCLC Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Targeted Drug VEGF Inhibitors for NSCLC Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Roche
9.1.1 Roche Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.1.2 Roche Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.1.4 Roche Business Overview
9.1.5 Roche Targeted Drug VEGF Inhibitors for NSCLC SWOT Analysis
9.1.6 Roche Recent Developments
9.2 Pfizer
9.2.1 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.2.2 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.2.4 Pfizer Business Overview
9.2.5 Pfizer Targeted Drug VEGF Inhibitors for NSCLC SWOT Analysis
9.2.6 Pfizer Recent Developments
9.3 Allergan
9.3.1 Allergan Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.3.2 Allergan Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.3.4 Allergan Targeted Drug VEGF Inhibitors for NSCLC SWOT Analysis
9.3.5 Allergan Business Overview
9.3.6 Allergan Recent Developments
9.4 Amgen
9.4.1 Amgen Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.4.2 Amgen Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.4.4 Amgen Business Overview
9.4.5 Amgen Recent Developments
9.5 Biocon
9.5.1 Biocon Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.5.2 Biocon Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.5.4 Biocon Business Overview
9.5.5 Biocon Recent Developments
9.6 Reliance Lifesciences
9.6.1 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.6.2 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.6.4 Reliance Lifesciences Business Overview
9.6.5 Reliance Lifesciences Recent Developments
9.7 Beaconpharma
9.7.1 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.7.2 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.7.4 Beaconpharma Business Overview
9.7.5 Beaconpharma Recent Developments
9.8 Celgene Corporation
9.8.1 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.8.2 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.8.4 Celgene Corporation Business Overview
9.8.5 Celgene Corporation Recent Developments
9.9 Fujifilm Kyowa Kirin Biologics
9.9.1 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.9.2 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.9.4 Fujifilm Kyowa Kirin Biologics Business Overview
9.9.5 Fujifilm Kyowa Kirin Biologics Recent Developments
9.10 Hetero Drugs
9.10.1 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Basic Information
9.10.2 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product Overview
9.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product Market Performance
9.10.4 Hetero Drugs Business Overview
9.10.5 Hetero Drugs Recent Developments
10 Targeted Drug VEGF Inhibitors for NSCLC Market Forecast by Region
10.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast
10.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Country
10.2.3 Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Region
10.2.4 South America Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Targeted Drug VEGF Inhibitors for NSCLC by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Targeted Drug VEGF Inhibitors for NSCLC by Type (2025-2030)
11.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Targeted Drug VEGF Inhibitors for NSCLC by Type (2025-2030)
11.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Forecast by Application (2025-2030)
11.2.1 Global Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units) Forecast by Application
11.2.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Targeted Drug VEGF Inhibitors for NSCLC Market Size Comparison by Region (M USD)
Table 5. Global Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2022)
Table 10. Global Market Targeted Drug VEGF Inhibitors for NSCLC Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Targeted Drug VEGF Inhibitors for NSCLC Sales Sites and Area Served
Table 12. Manufacturers Targeted Drug VEGF Inhibitors for NSCLC Product Type
Table 13. Global Targeted Drug VEGF Inhibitors for NSCLC Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Targeted Drug VEGF Inhibitors for NSCLC
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Targeted Drug VEGF Inhibitors for NSCLC Market Challenges
Table 22. Global Targeted Drug VEGF Inhibitors for NSCLC Sales by Type (K Units)
Table 23. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (M USD)
Table 24. Global Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units) by Type (2019-2024)
Table 25. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Type (2019-2024)
Table 26. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (M USD) by Type (2019-2024)
Table 27. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Type (2019-2024)
Table 28. Global Targeted Drug VEGF Inhibitors for NSCLC Price (USD/Unit) by Type (2019-2024)
Table 29. Global Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units) by Application
Table 30. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
Table 31. Global Targeted Drug VEGF Inhibitors for NSCLC Sales by Application (2019-2024) & (K Units)
Table 32. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Application (2019-2024)
Table 33. Global Targeted Drug VEGF Inhibitors for NSCLC Sales by Application (2019-2024) & (M USD)
Table 34. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2019-2024)
Table 35. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Growth Rate by Application (2019-2024)
Table 36. Global Targeted Drug VEGF Inhibitors for NSCLC Sales by Region (2019-2024) & (K Units)
Table 37. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Region (2019-2024)
Table 38. North America Targeted Drug VEGF Inhibitors for NSCLC Sales by Country (2019-2024) & (K Units)
Table 39. Europe Targeted Drug VEGF Inhibitors for NSCLC Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Sales by Region (2019-2024) & (K Units)
Table 41. South America Targeted Drug VEGF Inhibitors for NSCLC Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Sales by Region (2019-2024) & (K Units)
Table 43. Roche Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 44. Roche Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 45. Roche Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Roche Business Overview
Table 47. Roche Targeted Drug VEGF Inhibitors for NSCLC SWOT Analysis
Table 48. Roche Recent Developments
Table 49. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 50. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 51. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Pfizer Business Overview
Table 53. Pfizer Targeted Drug VEGF Inhibitors for NSCLC SWOT Analysis
Table 54. Pfizer Recent Developments
Table 55. Allergan Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 56. Allergan Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 57. Allergan Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Allergan Targeted Drug VEGF Inhibitors for NSCLC SWOT Analysis
Table 59. Allergan Business Overview
Table 60. Allergan Recent Developments
Table 61. Amgen Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 62. Amgen Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 63. Amgen Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Amgen Business Overview
Table 65. Amgen Recent Developments
Table 66. Biocon Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 67. Biocon Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 68. Biocon Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Biocon Business Overview
Table 70. Biocon Recent Developments
Table 71. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 72. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 73. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Reliance Lifesciences Business Overview
Table 75. Reliance Lifesciences Recent Developments
Table 76. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 77. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 78. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Beaconpharma Business Overview
Table 80. Beaconpharma Recent Developments
Table 81. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 82. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 83. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Celgene Corporation Business Overview
Table 85. Celgene Corporation Recent Developments
Table 86. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 87. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 88. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Fujifilm Kyowa Kirin Biologics Business Overview
Table 90. Fujifilm Kyowa Kirin Biologics Recent Developments
Table 91. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Basic Information
Table 92. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product Overview
Table 93. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Hetero Drugs Business Overview
Table 95. Hetero Drugs Recent Developments
Table 96. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Forecast by Region (2025-2030) & (K Units)
Table 97. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Targeted Drug VEGF Inhibitors for NSCLC Sales Forecast by Country (2025-2030) & (K Units)
Table 99. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Targeted Drug VEGF Inhibitors for NSCLC Sales Forecast by Country (2025-2030) & (K Units)
Table 101. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Sales Forecast by Region (2025-2030) & (K Units)
Table 103. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Targeted Drug VEGF Inhibitors for NSCLC Sales Forecast by Country (2025-2030) & (K Units)
Table 105. South America Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Forecast by Type (2025-2030) & (K Units)
Table 109. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Targeted Drug VEGF Inhibitors for NSCLC Price Forecast by Type (2025-2030) & (USD/Unit)
Table 111. Global Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units) Forecast by Application (2025-2030)
Table 112. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Targeted Drug VEGF Inhibitors for NSCLC
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (M USD), 2019-2030
Figure 5. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (M USD) (2019-2030)
Figure 6. Global Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (M USD)
Figure 11. Targeted Drug VEGF Inhibitors for NSCLC Sales Share by Manufacturers in 2023
Figure 12. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Manufacturers in 2023
Figure 13. Targeted Drug VEGF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Targeted Drug VEGF Inhibitors for NSCLC Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Targeted Drug VEGF Inhibitors for NSCLC Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type
Figure 18. Sales Market Share of Targeted Drug VEGF Inhibitors for NSCLC by Type (2019-2024)
Figure 19. Sales Market Share of Targeted Drug VEGF Inhibitors for NSCLC by Type in 2023
Figure 20. Market Size Share of Targeted Drug VEGF Inhibitors for NSCLC by Type (2019-2024)
Figure 21. Market Size Market Share of Targeted Drug VEGF Inhibitors for NSCLC by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application
Figure 24. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Application (2019-2024)
Figure 25. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Application in 2023
Figure 26. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2019-2024)
Figure 27. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application in 2023
Figure 28. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Growth Rate by Application (2019-2024)
Figure 29. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Region (2019-2024)
Figure 30. North America Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Country in 2023
Figure 32. U.S. Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Targeted Drug VEGF Inhibitors for NSCLC Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Targeted Drug VEGF Inhibitors for NSCLC Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Country in 2023
Figure 37. Germany Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Region in 2023
Figure 44. China Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (K Units)
Figure 50. South America Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Country in 2023
Figure 51. Brazil Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Targeted Drug VEGF Inhibitors for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share Forecast by Type (2025-2030)
Figure 65. Global Targeted Drug VEGF Inhibitors for NSCLC Sales Forecast by Application (2025-2030)
Figure 66. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share Forecast by Application (2025-2030)
